HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the...
Hence then, the article about akeso announces nmpa acceptance of second nda for gumokimab il 17a inhibitor in active ankylosing spondylitis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis )
Also on site :
- After the Fire, Hope Valley Faces Its First Reckoning in 'When Calls the Heart' Season 13 Episode 3
- Merz criticizes Germans for getting sick too often
- Simone Biles Stuns in Jonathan Owens-Inspired Outfit for NFL Playoff Game